Filtered By:
Source: Medscape Medical News Headlines
Drug: Angiomax
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
BRAVO 3 TAVR and AF: Stroke Risk, Discharge Meds Differ BRAVO 3 TAVR and AF: Stroke Risk, Discharge Meds Differ
In the BRAVO-3 trial of patients who had transfemoral TAVR with procedural bivalirudin or heparin, patients with new-onset AF had a much greater stroke risk; there was also an"incredible" variation in discharge meds.Heartwire from Medscape
Source: Medscape Medical News Headlines - May 12, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news
